NCT02327169 - A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2015

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions

Advanced Nonhematologic Malignancies

Interventions

DRUG

MLN2480

MLN2480 tablets.

DRUG

MLN0128

MLN0128 capsules.

DRUG

Alisertib

Alisertib tablets.

DRUG

Paclitaxel

Paclitaxel IV infusion.

DRUG

Cetuximab

Cetuximab IV infusion.

DRUG

Irinotecan

Irinotecan IV infusion.

Trial Locations (14)

2114

Massachusetts General Hospital Cancer Center, Boston

2115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

8035

Hospital Universitari Vall d'Hebron, Barcelona

19111

Fox Chase Cancer Center, Philadelphia

28040

START Madrid. Fundacion Jimenez Diaz, Madrid

29010

Hospital Clinico Universitario Virgen de la Victoria, Málaga

31059

Institut Claudius Regaud-Oncopole, Toulouse

33076

Institut Bergonie, Bordeaux

77030

The University of Texas MD Anderson Cancer Center, Houston

94805

Institut Gustave Roussy, Villejuif

W1G 6AD

Sarah Cannon Research Institure UK, London

M20 4BX

The Chrisie, Manchester

OX3 7LJ

Churchill Hospital, Oxford